Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biocept Inc (BIOC)

Biocept Inc (BIOC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,342
  • Shares Outstanding, K 16,904
  • Annual Sales, $ 61,250 K
  • Annual Income, $ -2,820 K
  • 60-Month Beta 0.66
  • Price/Sales 0.41
  • Price/Cash Flow N/A
  • Price/Book 0.67
Trade BIOC with:

Options Overview Details

View History
  • Implied Volatility 263.37% ( -76.50%)
  • Historical Volatility 56.76%
  • IV Percentile 96%
  • IV Rank 57.01%
  • IV High 404.54% on 05/02/22
  • IV Low 76.17% on 08/17/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 11
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 3,544
  • Open Int (30-Day) 3,613

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate -0.24
  • Number of Estimates 1
  • High Estimate -0.24
  • Low Estimate -0.24
  • Prior Year 0.19
  • Growth Rate Est. (year over year) -226.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4000 +2.86%
on 05/19/22
1.8000 -20.00%
on 04/21/22
-0.3300 (-18.64%)
since 04/20/22
3-Month
1.4000 +2.86%
on 05/19/22
2.4600 -41.46%
on 03/01/22
-0.9600 (-40.00%)
since 02/18/22
52-Week
1.4000 +2.86%
on 05/19/22
4.9700 -71.03%
on 06/22/21
-3.1000 (-68.28%)
since 05/20/21

Most Recent Stories

More News
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended...

BIOC : 1.4400 (-3.36%)
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 519,140...

BIOC : 1.4400 (-3.36%)
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 31, 2021 and provides a business...

BIOC : 1.4400 (-3.36%)
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and cash equivalents as of December...

BIOC : 1.4400 (-3.36%)
Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022

Biocept, Inc. (Nasdaq: BIOC) announces that it will release financial results for the three and 12 months ended December 31, 2021 and will file its Annual Report on Form 10-K with the Securities and Exchange...

BIOC : 1.4400 (-3.36%)
Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, highlighted the ability of its CNSide™ cerebrospinal fluid (CSF) assay to aid in therapeutic...

BIOC : 1.4400 (-3.36%)
Introduction of Innovative PCR-Based Detection Methods Surges Fueled by Pandemic and Other Diseases

Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary –  PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past...

GDBYF : 0.0323 (+19.19%)
GDBY.CN : 0.035 (-22.22%)
DOCRF : 0.3376 (+2.30%)
DOC.VN : 0.430 (-2.27%)
BIOC : 1.4400 (-3.36%)
CSTL : 21.65 (+10.29%)
SRNE : 1.5900 (+0.63%)
Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim President and Chief Executive Officer,...

BIOC : 1.4400 (-3.36%)
Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, has appointed Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer. With...

BIOC : 1.4400 (-3.36%)
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron...

BIOC : 1.4400 (-3.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept,...

See More

Key Turning Points

3rd Resistance Point 1.5425
2nd Resistance Point 1.5180
1st Resistance Point 1.4790
Last Price 1.4400
1st Support Level 1.4155
2nd Support Level 1.3910
3rd Support Level 1.3520

See More

52-Week High 4.9700
Fibonacci 61.8% 3.6063
Fibonacci 50% 3.1850
Fibonacci 38.2% 2.7637
Last Price 1.4400
52-Week Low 1.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar